#LCSM Chat Topic 4/2/2020: #COVID19 and #LungCancer

It seems that the world has turned upside down.  At the time I write this, there have been almost 550,00 cases of COVID-19 confirmed in the world and over 85,000 in the US.  Here in New York City there have been over 23,000 cases and 365 deaths as of March 27th (https://coronavirus.jhu.edu/map.html). The pandemic has placed enormous stress on our health care delivery system.  For lung cancer patients, it has affected healthcare providers’ ability to perform tests and radiologic procedures; provide timely diagnosis, staging, and care for early stage patients; and, in… Read More

#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing

Until just a few years ago, chemotherapy was often the only option for some cancer patients.  In just a few short years, molecular therapies and immunotherapies have become commonplace as treatments for cancer patients.  But determining whether a particular cancer patient is a candidate for these new, often very expensive, molecular and immunotherapies requires molecular biomarker testing.  For many cancer patients and their families, the role of molecular biomarker testing in their diagnosis is a unfamiliar and confusing.  How is testing performed?  How is the test result analyzed? What is involved in… Read More

#LCSM Chat Topic 03/07: Biomarker Magicians (or, Why We Love Pathologists)

Diagnosing the type of lung cancer from a tissue or liquid biopsy is absolutely critical to selecting treatment and determining the patient’s prognosis. However, for many lung cancer patients and their families, the role of tumor tissue in their diagnosis is a mystery. What happens to tissue collected in a biopsy? How is it analyzed? What is involved in getting helpful answers from biomarker testing? The specialized doctors responsible for answering these questions are pathologists.  They identify any lung cancer cells in the biopsied tissue, and guide the patient’s biomarker testing. Unfortunately,… Read More